Glenmark Pharma gets tentative nod from USFDA for acne treatment drug
New Delhi: Glenmark Pharmaceuticals Thursday it has received tentative approval from the US health regulator for Clindamycin Phosphate Foam, used to treat acne.
The approved product is a generic version of Mylan Pharmaceuticals' Evoclin Foam.
Glenmark Pharmaceuticals, USA, has been granted tentative approval by the United States Food and Drug Administration (USFDA) for Clindamycin Phosphate Foam, 1 per cent, the company said in a BSE filing.
For the 12 months to April 2019, Evoclin Foam market achieved annual sales of approximately USD 17 million, Glenmark said, citing IQVIA sales data.
The company's current portfolio consists of 156 products authorised for distribution at the US marketplace and 59 Abbreviated New Drug Applications (ANDAs) pending approval with the USFDA.
Read Also: Glenmark Pharma gets USFDA nod for generic version of Vesicare tablets
Next Story
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd